Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for heart failure
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
L-carnitine supplementation in the recovery of plasma L-carnitine in patients with heartfailure submitted to coronary artery bypass grafting. Coronary artery bypass grafting reduces plasma L-carnitine and may impair the production of myocardial energy. L-carnitine supplementation may elevate plasma L-carnitine and increase cardiac mechanical efficiency. The objective of this study was to verify the recovery of preoperative plasma LC in patients with heartfailure undergoing coronary artery (...) bypass grafting supplemented with a daily oral dose of 50 mg / kg. Volunteers with ischemic heartfailure who underwent surgery were randomized into a supplemented group (A-received 50 mg / kg L-carnitine) or placebo group (B) for 60 days. Supplementation was started on the third postoperative day. The spectrophotometric enzymatic method was used to quantify plasma L-carnitine. In the preoperative period, both groups had plasma L-carnitine adequate to the reference range (18.9-71.1 μM). On the second
Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With HeartFailure Although torsemide's oral bioavailability and half-life theoretically render it a more efficient diuretic than furosemide, the clinical outcomes of torsemide compared with furosemide remain unclear. We performed a systematic review and meta-analysis, including all published studies that compared torsemide and furosemide use in heartfailure patients from January 1996 through August 2019. Nineteen studies (9 (...) randomized control trials [RCTs] and 10 observational studies) with a total of 19,280 patients were included. During a mean follow-up duration of 15 months, torsemide was associated with a numerically lower risk of hospitalization due to heartfailure (10.6% vs 18.4%; odds ratio [OR] 0.72, 95% confidence interval [CI] [0.51, 1.03], p = 0.07, I2 = 18%; number needed to treat [NNT] = 23) compared with furosemide. Torsemide was associated with statistically significant more improvement in functional status
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without HeartFailure and HeartFailure-Related Outcomes: Insights From the EXSCEL Trial Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heartfailure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baseline heartfailure (HF) status. EQW's effects on secondary end points based on HHF
Optimizer Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic HeartFailure 1 Public Summary Document Application No. 1387.2 – Optimizer® Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic HeartFailure Applicant: Impulse Dynamics and Life Systems Date of MSAC consideration: MSAC 75 th Meeting, 28-29 March 2019 Context for decision: MSAC makes its advice in accordance (...) with its Terms of Reference, visit the MSAC website 1. Purpose of application An application for the resubmission of an implantable pulse generator (IPG) delivering Cardiac Contractility Modulation (CCM) therapy for patients with chronic heartfailure was received from Impulse Dynamics Australia Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness
Incidence of heartfailure after pacemaker implantation: a nationwide Danish Registry-based follow-up study The objective of the current study is to investigate the risk of heartfailure (HF) after implantation of a pacemaker (PM) with a right ventricular pacing (RVP) lead in comparison to a matched cohort without a PM and factors associated with this risk.All patients without a known history of HF who had a PM implanted with an RVP lead between 2000 and 2014 (n = 27 704) were identified using
Improving Communication in HeartFailure Patient Care Although implantable cardioverter-defibrillators (ICDs) reduce sudden death, these patients die of heartfailure (HF) or other diseases. To prevent shocks at the end of life, clinicians should discuss deactivating the defibrillation function.The purpose of this study was to determine if a clinician-centered teaching intervention and automatic reminders increased ICD deactivation discussions and increased device deactivation.In this 6-center
Identifying optimal doses of heartfailure medications in men compared with women: a prospective, observational, cohort study. Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and β blockers are similar for men and women with heartfailure with reduced ejection fraction (HFrEF), even though there are known sex differences in pharmacokinetics of these drugs. We hypothesised that there might be sex differences in the optimal (...) dose of ACE inhibitors or ARBs and β blockers in patients with HFrEF.We did a post-hoc analysis of BIOSTAT-CHF, a prospective study in 11 European countries of patients with heartfailure in whom initiation and up-titration of ACE inhibitors or ARBs and β blockers was encouraged by protocol. We included only patients with left ventricular ejection fraction less than 40%, and excluded those who died within the first 3 months. Primary outcome was a composite of time to all-cause mortality
Ivabradine for Adults with Stable Chronic HeartFailure: A Review of Clinical Effectiveness Ivabradine for Adults with Stable Chronic HeartFailure: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Ivabradine for Adults with Stable Chronic HeartFailure: A Review of Clinical Effectiveness Ivabradine for Adults with Stable Chronic HeartFailure: A Review of Clinical Effectiveness Last updated: May 15, 2019 Project Number: RC1119-000 Product Line: Research Type: Drug (...) Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of ivabradine for patients with stable chronic heartfailure and with left ventricular ejection fraction > 35% and 40%? Key Message There were no studies identified with inclusion criteria of patients with stable chronic heartfailure and left ventricular ejection fraction greater than 35% and less than or equal to 40% Two studies, however, included patients with LVEF less than 40% and were
Natriuretic Peptide Testing for Monitoring of HeartFailure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Monitoring of HeartFailure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Natriuretic Peptide Testing for Monitoring of HeartFailure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness (...) , and Guidelines Natriuretic Peptide Testing for Monitoring of HeartFailure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 19, 2019 Project Number: RC1163-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and clinical utility of natriuretic peptide testing for the monitoring of heartfailure therapy? What is the cost
Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic HeartFailure in Emergency Departments: Clinical Utility and Cost-Effectiveness Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic HeartFailure in Emergency Departments: Clinical Utility and Cost-Effectiveness | CADTH.ca Find the information you need Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic HeartFailure in Emergency Departments (...) : Clinical Utility and Cost-Effectiveness Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic HeartFailure in Emergency Departments: Clinical Utility and Cost-Effectiveness Last updated: August 27, 2019 Project Number: RB1380-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of point of care ultrasound for the assessment of patients with suspected or known chronic heartfailure
Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heartfailure 1 Translation of the key statement of the final report N16-02 Telemonitoring mithilfe von aktiven kardialen implantierbaren Aggregaten bei ventrikulärer Tachyarrhythmie sowie Herzinsuffizienz (Version 1.2; Status: 4 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German (...) original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N16-02 Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heartfailure 1 Extract of final report N16-02 Version 1.2 Telemonitoring using active cardiac implantable devices 4 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Telemonitoring using
Ivabradine (Lancora) for HeartFailure Ivabradine (Lancora) for HeartFailure | CADTH.ca Find the information you need Ivabradine (Lancora) for HeartFailure Ivabradine (Lancora) for HeartFailure Last updated: August 8, 2019 Project Number: HO0006-000 Product Line: Technology Review Result type: Report Heartfailure is a condition characterized by reduced cardiac output occurring due to complications of cardiovascular disease. It is a leading cause of hospital admissions and has a poor
Patients Hospitalized with HeartFailure: Risk Assessment, Management, and Clinical Trajectory EXPERT CONSENSUS DECISION PATHWAY 2019 ACC Expert Consensus Decision PathwayonRiskAssessment, Management, and Clinical Trajectory of Patients Hospitalized With HeartFailure A Report of the American College of Cardiology Solution Set Oversight Committee Writing Committee Steven M. Hollenberg, MD, FACC, Chair Lynne Warner Stevenson, MD, FACC, Vice Chair Tariq Ahmad, MD, MPH, FACC Vaibhav J. Amin, MD (...) ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With HeartFailure ... - APPENDIX 2 Peer Reviewer Relationships With Industry and Other Entities—2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and ClinicalTrajectoryofPatientsHospitalizedWithHeart Failure .. ... - APPENDIX 3 Abbreviations ... ... - APPENDIX 4 Advance Care Planning .. ... - APPENDIX 5 Alternative Format for the Focused Discharge Handoff
The Effect of Renal Denervation on Exercise Tolerance in Patients with HeartFailure "The Effect of Renal Denervation on Exercise Tolerance in Patients with" by Meredith Dahle < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: HeartFailure is a growing clinical syndrome that results in major impacts on patients and the medical system. Previously, therapy has (...) improved symptoms while leaving the patient disabled in the later stages. Renal denervation (RDN) is a procedure that is being researched for its effect on improving the condition of heartfailure along with its symptoms and increasing exercise tolerance in patients. Methods: Exhaustive search of available medical literature using MEDLINE via PubMed, CINAHL, Web of Science and Google Scholar using the keywords renal denervation, heartfailure and exercise tolerance. The studies that fit the eligibility
Cardiac rehabilitation for heartfailure can improve quality of life and fitness. The studyTaylor RS, Walker S, Ciani O, et al. Exercise-based cardiac rehabilitation for chronic heartfailure: the EXTRAMATCH II individual participant data meta-analysis. Health Technol Assess 2019;23:1-98.This project was funded by the NIHR Health Technology Assessment Programme (project number 15/80/30).To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000803/cardiac (...) -rehabilitation-for-heart-failure-can-improve-quality-of-life-and-fitness.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Dapagliflozin in Patients with HeartFailure and Reduced Ejection Fraction. In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heartfailure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heartfailure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.In this phase 3, placebo (...) -controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heartfailure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heartfailure (hospitalization or an urgent visit resulting in intravenous therapy for heartfailure) or cardiovascular death.Over a median of 18.2 months, the primary outcome occurred